Delving into the Latest Updates on Amphotericin B with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Amphotericin B lipid nanosphere, L-AMB, Liposomal amphotericin B

+ [27]

Target

Ergosterol

Mechanism

Ergosterol modulators(Ergosterol modulators)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesCardiovascular Diseases+ [4]

Active Indication

LeishmaniasisFebrile NeutropeniaMeningitis, Cryptococcal+ [14]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCandidiasis, Chronic Mucocutaneous+ [7]

Originator Organization

Vestar Development Co.

Active Organization

CSPC Ouyi Pharmaceutical Co., Ltd.CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.Astellas Pharma US, Inc.

+ [9]

Inactive Organization

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

Astellas Pharma, Inc.

DongKook Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1958),

Mycoses

RegulationOrphan Drug (US), Qualified Infectious Disease Product (US), Fast Track (US), Orphan Drug (EU)

Login to view timeline

Structure

Molecular FormulaC47H73NO17

InChIKeyAPKFDSVGJQXUKY-INPOYWNPSA-N

CAS Registry1397-89-3

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

Start Date06 Jan 2025

Sponsor / Collaborator

Duke University

[+6]

NCT05814432 / Not yet recruitingPhase 3IIT

Efficacy and Safety of High-dose Liposomal Amphotericin B (10 Mg/kg) for Disseminated Histoplasmosis in AIDS: a Randomized Phase III Trial (INDUCTION Trial)

Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).

Start Date01 Nov 2024

Sponsor / Collaborator

Immuno-Mycologics, Inc.

[+2]

CTRI/2024/09/074381 / Not yet recruitingPhase 4

A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B injection 50mg per vial (Lyophilized) TRASPOR (R) Manufactured by Emcure Pharmaceuticals LTD. in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice - NIL

Start Date31 Oct 2024

Sponsor / Collaborator

Emcure Pharmaceuticals Ltd.

100 Clinical Results associated with Amphotericin B

Login to view more data

100 Translational Medicine associated with Amphotericin B

Login to view more data

100 Patents (Medical) associated with Amphotericin B

Login to view more data

21,969

Literatures (Medical) associated with Amphotericin B

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity

Review

Author: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; He, Wuyang ; Liu, Cong ; An, Yunfei ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong

BACKGROUND:

Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.

OBJECTIVE:

We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.

METHODS:

A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.

RESULTS:

Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.

CONCLUSIONS:

The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Disseminated Aspergillosis in X-linked Agammaglobulinemia: Beyond the norm

Article

Author: Rawat, Amit ; Vignesh, Pandiarajan ; Jindal, Ankur Kumar ; Thangaraj, Abarna ; Goel, Sumit ; Sil, Archan

X-linked agammaglobulinemia (XLA) due to a mutation in Bruton's tyrosine kinase (BTK), leads to the arrested development of B cells at the pro-B cell stage. This results in absent B cells and severe hypogammaglobulinemia. XLA patients usually present with recurrent sinopulmonary infection. Bacterial infections are the commonest [2], fungal infections like Pneumocystis jirovecii, Aspergillus and Candida species are rarely reported and they are associated with mortality in XLA [3]. We report a 3.5-year-old boy with disseminated aspergillosis, an uncommon presentation of XLA. Despite treatment with antifungals, including voriconazole and amphotericin B, the patient succumbed to the illness. Genetic analysis revealed a pathogenic variant in the BTK gene (R28H), confirming XLA diagnosis. This case highlights the potential for severe fungal infections in XLA patients and suggests broader immune system dysregulation beyond B-cell defects.

01 Feb 2025·PARASITOLOGY INTERNATIONAL

Pulmonary infection by Lophomonas spp. and Aspergillus spp. in a B-cell acute lymphocytic leukemia patient from Chile

Article

Author: Moenen-Locoz, Enzo ; Cabrera, Johanna ; Chahin, Carolina ; Hidalgo, Alejandro ; Briones, Javier ; Iturrieta-González, Isabel ; Fonseca-Salamanca, Flery ; Vega, Fernando ; Concha, Carla

The flagellated protozoan Lophomonas spp. is a commensal microorganism found in the intestinal tracts of cockroaches, termites, mites, and certain birds. It is the causative agent of a rare infection in humans called lophomoniasis, primarily affecting the lungs and mainly immunocompromised individuals. This parasitosis is transmitted to humans by air or through ingestion of the cystic forms of the parasite. We describe the case of a 50-year-old patient treated at a tertiary hospital in southern Chile with a history of B-cell acute lymphocytic leukemia. Radiological findings, along with increased levels of inflammatory parameters and galactomannan antigen in serum and Bronchoaveolar Lavage (BAL) raised the suspicion of a pulmonary infection. Microscopic study of BAL revealed oval to pyriform cells with mobile flagella at the anterior end, which were identified as Lophomonas spp. trophozoites, which based on EORTC/MSG criteria were associated with diagnosis of a probable pulmonary aspergillosis. Lophomoniasis was treated with metronidazole (500 mg IV every 8 h) for 14 days and pulmonary aspergillosis required a combination of fluconazole, voriconazole, anidulafungin, liposomal amphotericin B and isavuconazole. The patient responded favorably and was discharged after 95 days of hospitalization. This case highlights the importance of recognizing lophomoniasis as a parasitic infection in respiratory samples from immunocompromised patients who present pulmonary symptoms, especially those who do not respond satisfactorily to conventional antimicrobial treatments. Further research is needed to understand the various sources of Lophomonas spp. infection and develop infection prevention strategies particularly for high-risk patients.

120

News (Medical) associated with Amphotericin B

31 Oct 2024

·www.globenewswire.com

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash. The departing senior executives include Chief Medical Officer Dr. James Ferguson, Chief Business Officer Thomas Hoover and Chief Technology Officer Dr. Hui Liu. The Board intends to retain an advisor to assist the Company with the potential asset sale of MAT2203, its lead Phase 3-ready antifungal drug candidate for the treatment of invasive fungal infections, and will evaluate other alternatives, including but not limited to winddown and dissolution of the Company. There can be no assurance that the Company will be able to sell MAT2203 on favorable terms, or at all. About MAT2203Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options. About Matinas BioPharmaMatinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. For more information, please visit www.matinasbiopharma.com. Forward-looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the sale of MAT2203 and the winddown and dissolution of the Company, and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to continue as a going concern, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use. Investor Contact Alliance Advisors IRJody Cain Jcain@allianceadvisors.com310-691-7100

Phase 3Phase 2

31 Oct 2024

·endpts.com

Boehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T study

Plus, news about Alnylam, Hutchmed, Wave Life Sciences and Matinas BioPharma: Boehringer Ingelheim ends work with Gubra on obesity drug: The German drugmaker stopped developing Gubra’s long-acting neuropeptide Y receptor type 2 (NPY2) agonist known as BI 1820237 . The pact , which started in 2017, could have led to about $262 million in milestones for Gubra, the company previously said. The termination doesn’t impact the duo’s three other programs, including a triple agonist for obesity that started a Phase 1 trial this summer. — Kyle LaHucik Galapagos resumes CAR-T trial: The Belgian drugmaker resumed enrollment in a Phase 1/2 study testing a BCMA CAR-T for certain multiple myeloma patients. The biotech had paused the study of GLPG5301 in August after a Parkinsonism event was seen in one patient. In its quarterly update, Galapagos also said it is looking for more external partners by way of research pacts, licensing deals or potential bolt-on acquisitions. — Kyle LaHucik Alnylam culls diabetes asset: The drugmaker stopped development of an RNAi therapy in Phase 1/2 for type 2 diabetes mellitus. The biotech attributed the termination to “portfolio prioritization efforts.” — Kyle LaHucik Hutchmed records $20M milestone: The payment from Takeda occurred after colorectal cancer treatment Fruzaqla generated $200 million in sales. The drug was approved by the FDA last year. — Jaimy Lee Wave Life Sciences said preclinical obesity data support improved durability: A single dose of Wave’s siRNA obesity treatment spurred “sustained change in body weight up to 12 weeks” in a mouse model. The data, presented Wednesday at Wave’s research day , suggest the potential for dosing only one or two times per year, according to the company. It also found that there was roughly two times greater weight loss when its siRNA was added onto a GLP-1 drug. — Max Bayer Matinas BioPharma lays off 15 workers: The New Jersey biotech ended negotiations for its oral formulation of amphotericin B and let go its chief medical officer, business chief and technology chief. It had 32 employees , as of March 18. Its stock $MTNB tumbled 65% on Thursday morning. — Kyle LaHucik

Phase 1Drug Approval

31 Oct 2024

·www.pharmaceutical-technology.com

Matinas BioPharma mulls wind-down as antifungal therapy deal falls through

Matinas BioPharma first reported in August that it had signed a non-binding term sheet for global licensing rights to MAT2203 for all future treatment indications. Image credit: Yellow_man / Shutterstock. Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management, in an effort to save resources after the partnership negotiations for its lead antifungal therapy were terminated. The company noted that the workforce reductions would occur with immediate effect. According to a Matinas press release, the company’s board is evaluating all alternatives, including the asset sale of MAT2203 (oral formulation of amphotericin B) and the potential wind-down and dissolution of the company. The company’s stock took a nosedive following the news. It is currently trading at $0.67, down by 65.2% compared to the market close yesterday (30 October). Martinas BioPharma’s market cap currently stands at $3.5m, with the company reporting cash reserves of $14.3m as of 30 June, as per the company’s Q2 financials. In August, Martinas reported that it had signed a non-binding term sheet for global licensing rights to MAT2203 for all future treatment indications. The company did not disclose the partner’s name or the financial details of the deal, only that it was preparing to start a Phase III registrational trial for the therapy following the partnership announcement. The study was expected to evaluate the therapy as an oral step-down monotherapy for patients with invasive aspergillosis following treatment with AmBisome (liposomal amphotericin B). MAT2203 was designed using the company’s lipid nanocrystal (LNC) platform to overcome the safety and toxicity limitations of intravenous amphotericin B. Despite being indicated to treat invasive fungal infections, intravenous amphotericin B is known to be toxic to kidneys and liver, with approximately 80% of patients developing infusion-related adverse effects or nephrotoxicity. Although there is an increased need for antimicrobial therapies , the field has not seen much success in recent years. Spero Therapeutics’ prodrug antibiotic SPR720 failed to meet the primary endpoint in a Phase IIa trial in patients with non-tuberculous mycobacterial pulmonary disease. AN2 Therapeutics also had to suspend development for its lead antibiotic, epetraborole, after it failed to show efficacy in the Phase II/III trial (NCT05327803). Itreum Therapeutics was able to receive approval from the US Food and Drug Administration (FDA) for its antibiotic Orlynvah (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs). The agency approved the therapy’s use for treating uUTIs caused by E. coli, Klebsiella pneumoniae or Proteus mirabilis in women who have limited or no alternative antibacterial treatment options.

Phase 2License out/inPhase 3Drug Approval

100 Deals associated with Amphotericin B

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00203	Amphotericin B	G01AA03 J02AA01 A01AB04	DB00681

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leishmaniasis	JP	Sumitomo Pharma Co., Ltd.	17 Jun 2009
Febrile Neutropenia	JP	Sumitomo Pharma Co., Ltd.	20 Apr 2006
Meningitis, Cryptococcal	US	Astellas Pharma US, Inc.	16 Jun 2000
Aspergillosis	US	Astellas Pharma US, Inc.	28 Jan 2000
Leishmaniasis, Visceral	US	Astellas Pharma US, Inc.	11 Aug 1997
Neutropenia	US	Astellas Pharma US, Inc.	11 Aug 1997
Candidiasis	JP	Fuji Pharma Co., Ltd.	31 Jan 1997
Invasive Fungal Infections	JP	Clinigen KK	18 Apr 1963
Mycoses	-	Bristol Myers Squibb Co.	01 Jan 1958
Complicated urinary tract infection	CN	-	-
Endocarditis, Bacterial	CN	-	-
Meningitis	CN	-	-
Sepsis	CN	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Candidiasis, Invasive	Phase 3	CN	CSPC Ouyi Pharmaceutical Co., Ltd.	23 Dec 2022
Deep mycosis	Phase 3	CN	CSPC Ouyi Pharmaceutical Co., Ltd.	23 Dec 2022
Fever	Phase 3	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	15 Dec 2021
Acute Lymphoblastic Leukemia	Phase 3	GB	Gilead Sciences, Inc.	01 Apr 2011
Invasive aspergillosis	Phase 3	NL	Gilead Sciences, Inc.	01 Jan 2000
Invasive Pulmonary Aspergillosis	Phase 3	NL	Gilead Sciences, Inc.	01 Jan 2000
Pre B-cell acute lymphoblastic leukemia	Phase 2	-	Matinas Biopharma Nanotechnologies, Inc.	01 Aug 2019
Candidiasis, Vulvovaginal	Phase 2	US	Matinas Biopharma Nanotechnologies, Inc.	01 Nov 2016
Yeast infection	Phase 2	US	Matinas Biopharma Nanotechnologies, Inc.	01 Nov 2016
Candidiasis, Chronic Mucocutaneous	Phase 2	US	Matinas Biopharma Nanotechnologies, Inc.	27 Sep 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GlobeNewswire Manual	Not Applicable	Fusariosis	3	MAT2203	ndilxyufeq(zdddmyjjuw) = omgluzxbho oqjqlrczfe (dkvchnzpqy )	Positive	22 Mar 2024
GlobeNewswire Manual	Not Applicable	Invasive Fungal Infections	19	MAT2203	nbrhearpvj(lowkvlchyu) = jmipelpwql tgacruvkha (ozcfpwroof ) View more	Positive	26 Feb 2024
NCT03399955 (not available, Pubmed \| PLoS Negl Trop Dis)	Phase 2	Post-Kala-azar dermal leishmanioid	110	Paromomycin/Miltefosine	rgisfdxyrw(qoomingchy) = jvkenrhtnm ytcruohoof (xxmjyzrmjz, 90.3 - 100)	Positive	21 Nov 2023
				Liposomal Amphotericin B/Miltefosine	rgisfdxyrw(qoomingchy) = noshkqzdbu ytcruohoof (xxmjyzrmjz, 70.2 - 91.9)
NCT05814432 (not available, Pubmed \| Clin Infect Dis)	Phase 2	CD4+	118	Single dose 10 mg/kg of L-AmB	opqkadotqy(wisfefzxyk) = cbpbyanait kaaztjwgei (gfgwtoiguu ) View more	Positive	13 Oct 2023
				10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3	opqkadotqy(wisfefzxyk) = gpgrshxswj kaaztjwgei (gfgwtoiguu ) View more
WCD2023	Not Applicable	Leishmaniasis, Cutaneous	28	Liposomal amphotericin B 12 mg/kg	ivkumrvova(nrtjzzyznz) = xhssppozjd vdmdcheyzn (ptceudtyde ) View more	Positive	06 Jul 2023
				Liposomal amphotericin B 18 mg/kg	ivkumrvova(nrtjzzyznz) = jclexwiymp vdmdcheyzn (ptceudtyde ) View more
ISN WCN2023	Not Applicable	Mucormycosis	-	Liposomal amphotericin (LAmB)	uxwvvobdmz(rjfrmaosbb) = zyskzsuexe qlcnecobwp (xgvcqsijvu ) View more	-	01 Mar 2023
ASN2022	Phase 2	AIDS-Related Opportunistic Infections cystatin C \| fractional excretion of sodium \| fractional excretions of potassium	90	Liposomal Amphotericin B 3 mg/kg for 14 days	otvdwieubt(lyvaswwcch) = zhrpsqaypw kpxymgruce (ssahftxhgg ) View more	Positive	03 Nov 2022
NCT04031833 (EnACT, Corporate Publications) Manual	Phase 2	Meningitis, Cryptococcal	80	Flucytosine+Fluconazole+MAT2203 (Cohort 4)	uxbpgnehya(pkxjfwahuu) = dyrrqnkyyz qvpgckvwyc (jncoeyylrc, 0.22 - 0.38) View more	Positive	21 Oct 2022
				Standard of Care	ohzagfbjxq(ftacinbsgd) = yzwmyayhdf qiiwkwmvqq (ytjxmgsimy ) View more
ISN WCN2022	Not Applicable	Peritoneal dialysis-associated peritonitis	48	Intravenous amphotericin B and oral flucytosine	xnfgcbinnn(pgtlzhxsnv) = zvfcvlqulx zwozdbodrs (cdjwpzhpor ) View more	Negative	01 Feb 2022
				Intraperitoneal amphotericin B and oral flucytosine	xnfgcbinnn(pgtlzhxsnv) = tnmpreqzcx zwozdbodrs (cdjwpzhpor ) View more
IAS2022	Not Applicable	Talaromycosis	170	Amphotericin B deoxycholate-based induction therapy	pwahfnmhjn(gxtcsejogu) = cemhlndapl uaxgdaondy (itkoovujsh ) View more	-	01 Jan 2022